
|Articles|January 1, 2003
Systemic retinoid chemoprophylaxis causes frequent adverse events for immunosuppressed transplant patients with advanced SCC
Chicago -- Although published clinical trial results suggest systemic retinoid therapy administered for skin cancer chemoprevention in immunosuppressed organ transplant recipients is well tolerated despite causing frequent adverse events,
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5











